---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013816"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:18:22.674855+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months

## Summary
- Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.
- Final Phase 2 OVATION 2 data show median OS improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001+SoC vs SoC alone.
- Phase 3 OVATION 3 enrollment ahead of plan; first patient dosed in Q3 2025.
- Cash and cash equivalents $8.8M as of Dec 31, 2025; $7M registered direct offering closed Dec 2025.
- Strategic reorganization Feb 2026 to reduce expenses and focus on Phase 3 study.

## SEC filing metadata
- accession: 0001493152-26-013816
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013816
- JSON: https://secwatch.observer/filing/0001493152-26-013816.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013816.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/0001493152-26-013816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.